Cyclerion Therapeutics Stock Price on June 17, 2024
| CYCN Stock | USD 2.75 0.18 6.14% |
Below is the normalized historical share price chart for Cyclerion Therapeutics extending back to March 18, 2019. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Cyclerion Therapeutics stands at 2.75, as last reported on the 23rd of September, with the highest price reaching 2.94 and the lowest price hitting 2.75 during the day.
If you're considering investing in Cyclerion Stock, it is important to understand the factors that can impact its price. Cyclerion Therapeutics appears to be dangerous, given 3 months investment horizon. Cyclerion Therapeutics secures Sharpe Ratio (or Efficiency) of 0.0471, which signifies that the company had a 0.0471% return per unit of standard deviation over the last 3 months. By analyzing Cyclerion Therapeutics' technical indicators, you can evaluate if the expected return of 0.52% is justified by implied risk. Please makes use of Cyclerion Therapeutics' risk adjusted performance of 0.0777, and Mean Deviation of 6.96 to double-check if our risk estimates are consistent with your expectations.
At this time, Cyclerion Therapeutics' Sale Purchase Of Stock is very stable compared to the past year. As of the 23rd of September 2024, Stock Based Compensation To Revenue is likely to grow to 19.89, while Total Stockholder Equity is likely to drop about 10.7 M. . At this time, Cyclerion Therapeutics' Price To Sales Ratio is very stable compared to the past year. As of the 23rd of September 2024, Price Book Value Ratio is likely to grow to 0.73, while Price Earnings Ratio is likely to drop (0.39). Cyclerion Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 2nd of April 2019 | 200 Day MA 3.0343 | 50 Day MA 3.0203 | Beta 1.91 |
Cyclerion |
Sharpe Ratio = 0.0471
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CYCN | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 11.07 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.52 actual daily | 10 90% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 3 97% of assets perform better |
Based on monthly moving average Cyclerion Therapeutics is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cyclerion Therapeutics by adding it to a well-diversified portfolio.
Price Book 0.8336 | Enterprise Value Ebitda 0.563 | Price Sales 55.5007 | Shares Float 1.2 M | Wall Street Target Price 4 |
Related Headline
X4 Pharmaceuticals Headline on 17th of June 2024
Kingdon Capital Management L.L.C. Raises Stock Position in X... by news.google.com
Kingdon Capital Management L.L.C. Raises Stock Position in X4 Pharmaceuticals, Inc. MarketBeat
Cyclerion Therapeutics Valuation on June 17, 2024
It is possible to determine the worth of Cyclerion Therapeutics on a given historical date. On June 17, 2024 Cyclerion was worth 2.74 at the beginning of the trading date compared to the closed value of 2.79. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Cyclerion Therapeutics stock. Still, in general, we apply an absolute valuation method to find Cyclerion Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Cyclerion Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Cyclerion Therapeutics' related companies.
| Open | High | Low | Close | Volume | |
| 2.45 | 2.97 | 2.42 | 2.72 | 6,874 | |
06/17/2024 | 2.74 | 2.95 | 2.72 | 2.79 | 8,613 |
| 2.85 | 3.09 | 2.18 | 2.21 | 13,607 |
| Backtest Cyclerion Therapeutics | | | Cyclerion Therapeutics History | | | Cyclerion Therapeutics Valuation | Previous | Next |
Cyclerion Therapeutics Trading Date Momentum on June 17, 2024
| On June 18 2024 Cyclerion Therapeutics was traded for 2.21 at the closing time. The top price for the day was 3.09 and the lowest listed price was 2.18 . The trading volume for the day was 13.6 K. The trading history from June 18, 2024 was a factor to the next trading day price decrease. The overall trading delta against the next closing price was 20.79% . The overall trading delta against the current closing price is 16.85% . |
Cyclerion Therapeutics Fundamentals Correlations and Trends
By evaluating Cyclerion Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Cyclerion Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Cyclerion financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Cyclerion Therapeutics Stock history
Cyclerion Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Cyclerion is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Cyclerion Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Cyclerion Therapeutics stock prices may prove useful in developing a viable investing in Cyclerion Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 2.3 M | 1.9 M | |
| Net Loss | -50.7 M | -53.2 M |
Cyclerion Therapeutics Quarterly Net Working Capital |
|
Cyclerion Therapeutics Stock Technical Analysis
Cyclerion Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Cyclerion Therapeutics Period Price Range
Low | September 23, 2024
| High |
0.00 | 0.00 |
Cyclerion Therapeutics cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Cyclerion Therapeutics September 23, 2024 Market Strength
Market strength indicators help investors to evaluate how Cyclerion Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Cyclerion Therapeutics shares will generate the highest return on investment. By undertsting and applying Cyclerion Therapeutics stock market strength indicators, traders can identify Cyclerion Therapeutics entry and exit signals to maximize returns
Cyclerion Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Cyclerion Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Cyclerion Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Cyclerion to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.0777 | |||
| Jensen Alpha | 0.6658 | |||
| Total Risk Alpha | (0.64) | |||
| Sortino Ratio | 0.1038 | |||
| Treynor Ratio | 0.4008 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Additional Information and Resources on Investing in Cyclerion Stock
When determining whether Cyclerion Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cyclerion Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cyclerion Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cyclerion Therapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclerion Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Cyclerion Stock, please use our How to Invest in Cyclerion Therapeutics guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclerion Therapeutics. If investors know Cyclerion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclerion Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.29) | Revenue Per Share 0.586 | Quarterly Revenue Growth 0.141 | Return On Assets (0.47) | Return On Equity (1.50) |
The market value of Cyclerion Therapeutics is measured differently than its book value, which is the value of Cyclerion that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclerion Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclerion Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclerion Therapeutics' market value can be influenced by many factors that don't directly affect Cyclerion Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclerion Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclerion Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclerion Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.